Early Safety From Phase 1b/3, Multicenter, Open-Label, Randomized Trial Of Talimogene Laherparepvec (T-Vec) Plus Pembrolizumab (Pembro) For Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck (R/M Scchn): Masterkey-232
ANNALS OF ONCOLOGY（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要